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The NLRP3 inflammasome regulates production of the pro-inflammatory cytokines interleukin-1b (IL-1b)
and IL-18, and contributes to inflammation exacerbating disease. Fenamate non-steroidal anti-
inflammatory drugs (NSAIDs) were recently described as NLRP3 inflammasome inhibitors via chloride
channel inhibition. Fenamate NSAIDs inhibit cyclooxygenase (COX) enzymes, limiting their potential as
therapeutics for NLRP3-associated diseases due to established side effects. The aim here was to develop
properties of the fenamates that inhibit NLRP3, and at the same time to reduce COX inhibition. We
synthesised a library of analogues, with feedback from in silico COX docking potential, and IL-1b release
inhibitory activity. Through iterative screening and rational chemical design, we established a collection
of chloride channel inhibiting active lead molecules with potent activity at the canonical NLRP3
inflammasome and no activity at COX enzymes, but only in response to stimuli that activated NLRP3 by
a K+ efflux-dependent mechanism. This study identifies a model for the isolation and removal of
unwanted off-target effects, with the enhancement of desired activity, and establishes a new chemical
motif for the further development of NLRP3 inflammasome inhibitors.Introduction
Inammation is known to contribute to the worsening of many
diseases, and is frequently associated with the activation of the
NOD-like receptor pyrin domain-containing protein 3 (NLRP3)
inammasome.1 NLRP3 is studied mainly in cells of the innate
immune system such as macrophages where it responds to
danger in the form of pathogen or damage-associated molec-
ular patterns (PAMPs or DAMPs respectively). Upon sensing
danger NLRP3 interacts with an adaptor protein called
apoptosis-associated speck-like protein containing a CARD
(ASC) causing its oligomerisation into an activating platform for
the protease caspase-1. Caspase-1 then cleaves pro-Psychology, School of Biological Sciences,
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tion (ESI) available. See DOI:
728inammatory cytokine precursors pro-IL-18 and pro-IL-1b into
active forms that are then secreted from the cell.1 Caspase-1 also
cleaves the pore-forming protein gasdermin D (GSDMD) which
subsequently forms membrane pores causing pyroptotic cell
death.2,3 A number of inhibitors of the NLRP3 inammasome
have been described such as CRID3/MCC950/CP-456773 which
binds directly to NLRP3.4,5 We previously reported that fena-
mate NSAIDs are also able to inhibit NLRP3 inammasome
activation in vitro and in vivo by virtue of their ability to act on
Cl channels.6 Targeting the regulatory pathways of NLRP3 may
complement strategies to inhibit the protein directly. Fenamate
targeting of Cl channels however is complicated by their
primary effects at cyclooxygenase (COX) enzymes which is
associated with signicant side effects with long term use.
Thus, the aim of this study was to develop the NLRP3
inhibiting properties of the fenamate scaffold and deselect the
COX inhibiting properties. Using cycles of iterative chemistry,
computational modelling of COX inhibition and biological
measurement of effects against the NLRP3 inammasome, we
have developed inhibitors that block NLRP3 via Cl channel
inhibition and that are devoid of activity against COX.
Furthermore, targeting Cl channels only inhibited K+-depen-
dent canonical NLRP3 activation. This offers the advantage now
of selective NLRP3 pathway modulation in diseases which may
help mitigate potentially immunosuppressive effects of
a blanket NLRP3 inhibition.This journal is © The Royal Society of Chemistry 2020
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Full details of the synthesis and characterisation for all
compounds are provided in the ESI Chemistry le.† All other
pharmacological reagents were obtained from Sigma (Niumic
acid (NFA), Tolfenamic acid (TFA), Flufenamic acid (FFA), Clo-
nixin, Furosemide, SB 225002, U-104, S4, Celecoxib, Mefenamic
acid, Bay 11-7082, MCC950 and Ac-Tyr–Val–Ala–Asp-
chloromethylketone (Ac-YVAD-CMK)).
Cell culture
Primary BMDMs. For the preparation of primary bone
marrow derived macrophages (BMDMs), wild-type C57BL/6
(Charles River) mice were euthanized by rising CO2, followed
by cervical dislocation. All procedures were carried out in
accordance with the Home Office (Animals) Scientic Proce-
dures Act (1986). Bone marrow was isolated from the femur and
tibia bones of C57BL/6 mice and re-suspended in ACK lysis
buffer (Fisher Scientic) for lysis of red blood cells. The
remaining cells were cultured in L929-containing Dulbecco's
Modied Eagle's Medium (DMEM) with 10% (vol/vol) fetal
bovine serum (FBS, Life Technologies), 100 U ml1 penicillin
and 100 mg ml1 streptomycin (1% P/S, Sigma). On day 6–7, cells
were scraped and seeded overnight at a density of 1  106 ml1
in 24- or 96-well plates.
ASC-mCherry iBMDMs. Immortalised BMDMs stably
expressing ASC conjugated to mCherry6 were cultured in DMEM
with 10% (vol/vol) FBS and 1% (vol/vol) P/S and seeded over-
night at a density of 0.75  106 ml1 in black-walled, clear
bottom 96 well plates.
CD14+ monocytes. Full consent from human volunteers
(National Health Service Blood and Transplant, Manchester, UK)
and ethical approval from the Research Governance, Ethics, and
Integrity Committee at The University of Manchester was obtained
prior to experiments (ref. 2018-2696-5711). Blood was collected
from healthy human donors and peripheral blood mononuclear
cells (PBMCs) were isolated using Ficoll (Thermosher) gradient
density centrifugation at 500 g for 40 min at room temperature.
The PBMC layer was collected and platelets, plasma proteins and
further contaminants were removed by washing with MACS buffer
(PBS containing 0.5% (w/vol) BSA and 2 mM EDTA) followed by
centrifugation at 500 g for 10 min at room temperature. PBMCs
were incubated with MACS CD14+ MicroBeads (Miltenyi) for
15 min at 4 C and CD14+ monocytes were pulled out using a LS
column (Miltenyi). CD14+ monocytes were cultured in RPMI-1640
(Thermosher) supplemented with 1% (vol/vol) FBS, 2 mM L-
glutamine (Sigma) and 1% (vol/vol) P/S and seeded at a density of 2
 106 ml1 in round-bottom 96-well plates.
HeLa cells.HeLa cells were cultured in DMEMcontaining 10%
(vol/vol) FBS and 1% (vol/vol) P/S and seeded at a density of 1 
105 ml1 overnight before transfection the following morning.
Inammasome assays
BMDMs were primed with 1 mg ml1 lipopolysaccharide (LPS)
from Escherichia coli (serotype O26:B6, Sigma) in DMEMThis journal is © The Royal Society of Chemistry 2020containing 10% (vol/vol) FBS and 1% (vol/vol) P/S for 4 h, fol-
lowed by pre-treatment with NVR compound (10 mM), NS3728
(10 mM), MCC950 (10 mM) or vehicle (DMSO (0.5%, vol/vol),
Sigma) in serum-free DMEM at indicated concentrations for
15 min. To induce canonical NLRP3 activation, 5 mM ATP
(Sigma) or 75 mM imiquimod (InvivoGen) was added directly to
wells for 1 or 2 h, respectively. Alternatively, hypotonic buffer
(27 mM NaCl, 0.54 mM KCl, 0.3 mM KH2PO4, 0.5 mM MgCl2,
0.9 mM CaCl2, 20 mM HEPES, 5 mM NaHCO3 and 3 mM
glucose, pH 7.4, 117 mOsm kg1 (ref. 7)) was added to LPS-
primed (1 mg ml1; 4 h) BMDMs for 4 h pre-treated with NVR
compound (10 mM), NS3728 (10 mM), MCC950 (10 mM) or vehicle
(DMSO (0.5%)) to induce NLRP3 activation. Isotonic buffer
(132 mM NaCl, 2.6 mM KCl, 1.4 mM KH2PO4, 0.5 mM MgCl2,
0.9 mM CaCl2, 20 mM HEPES, 5 mM NaHCO3 and 3 mM
glucose, pH 7.4, 340 mOsm kg1 (ref. 7)) was used as control.
For NLRC4 or AIM2 inammasome activation, LPS-primed (1 mg
ml1; 4 h) BMDMs were pre-treated with NVR compound (10
mM), NS3728 (10 mM), MCC950 (10 mM), Ac-YVADCMK (100 mM)
or vehicle (DMSO (0.5%)) for 15 min in serum-free DMEM and
then transfected with either 1 mg ml1 agellin from Salmonella
typhimurium (Invivogen) or 1 mg ml1 poly(deoxyadenylic-
thymidylic) acid sodium salt (poly(dA:dT), Sigma), respec-
tively, using Lipofectamine 3000 (Thermosher) per manufac-
turer's instructions, for 4 h. For BMDM priming experiments,
cells were pre-treated with NVR compound (10 mM), MCC950 (10
mM) or vehicle (DMSO (0.5%)) in serum-free DMEM for 15 min
followed by 4 h treatment with 1 mg ml1 LPS. For alternative
inammasome activation, primary human CD14+ monocytes
were seeded and immediately treated with 1 mg ml1 LPS in
RPMI-1640 supplemented with 1% FBS, 2 mM L-glutamine and
1% P/S for 20 h in the presence of NVR compound (10 mM),
NS3728 (10 mM), MCC950 (10 mM) or vehicle (DMSO (0.5%).
ELISA analysis
IL-1b, IL-6 and TNF, were analysed by ELISA according to
manufacturer's instructions (DuoSet, R&D Systems).
Western blot
Lysates and/or supernatants were assessed by western blot for
NLRP3, IL-1b, caspase-1, and GSDMD. Samples were run on SDS
polyacrylamide gels and transferred onto nitrocellulose or PVDF
membranes using a semi-dry Trans-blot Turbo system (Bio-Rad)
at 25 V. Membranes were blocked with 2.5% BSA in phosphate-
buffered saline, 0.1% Tween 20 (Sigma) (PBST) for 1 h before
overnight incubation at 4 C with mouse anti-NLRP3 mono-
clonal antibody (Cryo2, Adipogen), goat anti-IL-1b polyclonal
antibody (AF-401, R&D Systems), rabbit anti-caspase-1 + p10 +
p12 monoclonal antibody (EPR16883, Abcam), or rabbit anti-
GSDMD antibody (EPR19828, Abcam) in 2.5% BSA PBS-T. The
following morning, membranes were washed (5 min, 3) in
PBST and subsequently incubated with either rabbit anti-
mouse, rabbit anti-goat or goat anti-rabbit HRP antibodies
(Dako) in 2.5% PBST for 1 h at room temperature. b-Actin was
used as a sample loading control using a monoclonal anti-b-
Actin-peroxidase antibody (Sigma). Aer washing, AmershamChem. Sci., 2020, 11, 11720–11728 | 11721
Chemical Science Edge ArticleECL prime detection reagent (GE Healthcare) was added to
membranes and images were taken with a G:Box Chemi XX6
(Syngene) scanner.
ASC speck imaging
ASC-mCherry iBMDMs were primed with 1 mg ml1 LPS in
DMEM containing 10% FBS and 1% P/S for 2 h. Media was
replaced with OptiMEM (Thermosher) containing the irre-
versible caspase-1 inhibitor Ac-YVAD-CMK (100 mM; Sigma) to
prevent pyroptosis and either NVR compound (10 mM), NS3728
(10 mM), MCC950 (10 mM) or vehicle (DMSO (0.5%)) for 15 min
followed by stimulation with ATP (5 mM). ASC speck formation
was assessed in real-time with an IncuCyte ZOOM system (Essen
Bioscience). Images were acquired using a 10/0.3 s Plan Fluor
objective every 10 min for a period of 90 min. ASC speck
formation was compared between treatments at the 90min time
point. Specks were counted using ImageJ and speck formation
was calculated as a percentage of vehicle-treated cells.
COX2 in silico selectivity model
The structure of COX2 (PDB CODE 5IKQ) was prepared using
Schrodinger 2019.3. All water and ligands were removed, and
protonation states were adjusted (pH ¼ 7.4) along with the
optimization of the side chain orientations. The grid was then
prepared using Schrodinger grid preparation tool and was used
in a KNIME workow for further docking and classication
tasks. Ligands were prepared using LigPrep and docking per-
formed using Glide SP. Five known COX inhibitors (Niumic
acid, Tolfenamic acid, Clonixin, Flufenamic acid and Tromaril)
were docked and their average docking score and standard
deviation were determined (average docking score ¼ 8.35; s ¼
1.61). The standard deviation (s) was then used to classify other
docked ligands into different categories: high risk < 8.35 + 1s,
8.35 + 1s < medium high < 8.35 + 2s, 8.35 + 2s < medium
low risk < 8.35 + 3s, and low risk > 8.35 + 3s. Physico-
chemical parameters were also computed using ChemAxon
soware to calculate the MPO and BBB score.
COX assays
A Cayman chemical COX activity assay (Cayman chemical,
catalogue number 760111) was used to assay COX inhibition for
each drug (Mefenamic acid, Celecoxib, NVR compound or
NS3728 (10 mM)) or vehicle (DMSO (0.5%)). Drugs were assayed
in duplicate in a 96 well plate in independent experiments.
Puried COX1 or COX2 were incubated with each drug or
vehicle at indicated concentrations for 30 min before addition
of arachidonic acid, KOH and colorimetric substrate as per the
manufacturer's instructions. Aer 2 min, absorbance at 590 nm
was read using a plate reader (Synergy HT, BioTek). For calcu-
lation of COX activity, background absorbance from wells con-
taining no COX1 or COX2 was rst subtracted from each value.
Total COX activity for each drug was then calculated by
comparison of absorbance values to wells containing vehicle
(reference value set as 100% to which all other absorbance
values were compared) and expressed as the percentage of total
COX activity.11722 | Chem. Sci., 2020, 11, 11720–11728Iodide quenching assay
HeLa cells were transfected with pcDNA3.1EYFP H148Q, kindly
provided by Peter Haggie (Addgene #25872), for 18–24 h using
Lipofectamine 3000 (Thermosher) as per manufacturer's
instructions. Cells were washed twice with isotonic buffer (310
mOsm kg1, 140 mM NaCl, 5 mM KCl, 20 mM HEPES, pH 7.4)
and then incubated in 50 ml isotonic buffer containing NVR
compound (10 mM) or vehicle (DMSO (0.5%)) at 37 C for 5 min.
50 ml hypotonic (120 mOsm kg1, 5 mM KCl, 20 mM HEPES,
90 mM mannitol, pH 7.4) solution containing either NVR
compound (10 mM) or vehicle (DMSO (0.5%)) was then added
directly to wells for 5 min. Wells treated with isotonic buffer
were used as controls. To induce quenching of YFP uores-
cence, 25 ml of 200 mM sodium iodide (NaI; Sigma) was then
spiked directly into the well and uorescence readings were
taken every 2 s for 1 min using the FlexStation 3 plate reader.
Baseline uorescence readings (F0) before the addition of NaI
were taken in order to calculate the uorescence intensity ratio
(F/F0).Statistical analyses
All data are presented as mean S.E.M unless stated otherwise.
Statistical analyses were performed on GraphPad Prism 8. Data
were assessed for normality and homoscedasticity using Sha-
piro Wilk's and Levene's test, respectively, and transformed
where appropriate. Where data is normalised as a percentage,
a one-tailed, one-sample t-test was performed to determine
signicant difference from 100%, followed by Holm–Sidak
correction. A one-way or two-way ANOVA with either Dunnett's
or Holm–Sidak post hoc analysis was used to compare treat-
ments against a vehicle control, or selected treatments,
respectively, where accepted levels of signicance were *p <
0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.Results and discussion
In the rst instance we synthesised fenamate analogues
(designated as NVR compounds) where we (A) linked the phenyl
rings by an amine (ESI Fig. 1†), (B) linked the phenyl rings by an
amide (ESI Fig. 2†), and (C) linked the phenyl rings by a urea.
The carboxylic acid group in the fenamates was also replaced
with a tetrazole ring, and analogues with a range of substituents
on the phenyl rings were prepared (ESI Fig. 3†). Other modi-
cations were made including ureas lacking an acidic group (ESI
Fig. 4†), cyclised urea analogues (ESI Fig. 5†), a series of
unsubstituted linker analogues (ESI Fig. 6†), cyclic boron-
containing analogues (ESI Fig. 7†), as well as three commer-
cially available bioactive ureas and furosemide (ESI Fig. 8†).
These molecules were screened in LPS (1 mg ml1, 4 h)-primed
mouse primary bone marrow-derived macrophages (BMDMs),
being added at 10 mM just before the addition of ATP (5 mM, 60
min) to activate NLRP3. IL-1b release was quantied by ELISA.
From this experiment the class of molecule with the greatest
inhibition of NLRP3-dependent IL-1b release were those with
the urea linker (ESI Fig. 3†), with the amine and amide linkerThis journal is © The Royal Society of Chemistry 2020
Fig. 1 Identification of a sub-set of urea-based molecules with potent NLRP3 inhibition and low COX2 activity. (A) Representation of the
workflow used to classify the risk of COX2 inhibition. The known COX inhibitors Niflumic acid, Tolfenamic acid, Clonixin, Flufenamic acid and
Tromaril were docked into the COX2 crystal structure (PDB code 5IKQ). Their docking score was averaged (mean docking score ¼ 8.35) and
was used along with the standard deviation (s, s ¼ 1.61) to classify the designed compounds (n ¼ 106) in to various risk categories: high (H),
medium high (MH), medium low (ML) and low (L) risk. (B) Murine bone marrow-derived macrophages (BMDMs) were primed with LPS (1 mg ml1,
4 h) followed by treatment with NVR compound (10 mM), NS3728 (10 mM), or vehicle (DMSO, 0.5%) for 15min before stimulation with ATP (5mM, 1
h). Supernatants were collected and IL-1b release was determined by ELISA. Docking scores were then plotted against the % inhibition of IL-1b
release at 10 mM. Compounds in the low-risk COX2 category that inhibited IL-1b release by more than 80% (compared to vehicle) are shown in
the grey quadrant. (C) Highlighted compounds from B with high IL-1b release inhibition and low COX activity. Data are presented as mean
percentage inhibition of IL-1b release compared to vehicle control of at least two experiments.
This journal is © The Royal Society of Chemistry 2020 Chem. Sci., 2020, 11, 11720–11728 | 11723
Edge Article Chemical Science
Fig. 2 Characterisation of the properties of the improved inflammasome inhibiting sub-set. (A) Table of the most active urea-based sub-set of NLRP3
inhibitors with the general structure type (i), (ii) or (iii). Tet¼ 1H-tetrazol-5-yl. To obtain IL-1b half-maximal inhibitory concentration (IC50) values for these
inhibitors, supernatants were collected from LPS-primed BMDMs (1 mg ml1; 4 h) pre-treated with either NVR compound, NS3728 (0.03–100 mM) or
vehicle (DMSO, 0.5%) for 15min before stimulationwith ATP (5mM; 1 h). IL-1b releasewas assessedby ELISA anddata are expressed as ameanpercentage
versus vehicle of at least three independent experiments. Dose–response curves were fitted using either a 3- or 4-parameter logistical sigmoidal model.
Physicochemical properties were also calculated using ChemAxon software to generate the multiparameter optimisation (MPO) and blood–brain barrier
(BBB) score, predictors of CNS permeability. (B) Structure–activity relationship of inhibition of NLRP3-dependent IL-1b release as exemplified by the
structure of NVR-12. (C) IC50 graph for NVR-12, a representative molecule from the sub-set of urea-based inhibitors.
11724 | Chem. Sci., 2020, 11, 11720–11728 This journal is © The Royal Society of Chemistry 2020
Chemical Science Edge Article
Fig. 3 NVRs are selective inhibitors of the K+ efflux sensitive NLRP3 activation pathway. (A) HeLa cells were transfected with the halide-sensitive
YFP mutant (EYFP H148Q/I152L). Cells were placed in either isotonic (310 mOsm kg1) or hypotonic buffer (215 mOsm kg1) containing either
NVR-12 (10 mM) or vehicle (DMSO; 0.5%) for 5 min. Fluorescence readings were taken every 2 s before the addition of sodium iodide (NaI) to
obtain an average baseline fluorescence value (F0). NaI (200mM) was then spiked directly into the well to induce quenching of YFP fluorescence,
and fluorescence readings were maintained every 2 s for a further 1 min. Data are expressed as mean F/F0 + S.E.M (n ¼ 4). (B) LPS-primed (1 mg
ml1; 2 h) ASC-mCherry iBMDMs were pre-treated with NVR-12 (10 mM), MCC950 (10 mM) or vehicle (DMSO; 0.5%), and Ac-YVAD-CMK (100 mM)
to prevent pyroptosis, for 15 min prior to the addition of ATP (5 mM; 90 min) under live microscopy. Scale bars are 20 mm. Specks are denoted by
This journal is © The Royal Society of Chemistry 2020 Chem. Sci., 2020, 11, 11720–11728 | 11725
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Chemical Science Edge Articleseries, and the other analogues possessing minimal inhibitory
activity at this concentration (ESI Fig. 1–2 and 4–8).†
As stated above, NSAIDs are established COX inhibitors thus
the fenamates cannot be considered as selective NLRP3 inhib-
itors. To screen the potential for COX inhibition of the new
analogues we established a work-ow that used docking as
a proxy for the likelihood of interaction with COX enzymes
(Fig. 1A). Given that NSAID-related side effects are most closely
associated with inhibition of COX2 enzymes, all molecules,
including the known COX inhibitors Niumic acid, Tolfenamic
acid, Clonixin, Flufenamic acid and Tromaril, were docked in
the COX2 crystal structure (PDB code 5IKQ) (Fig. 1A). The
docking score of the known COX inhibitors was calculated
(average docking score ¼ 8.35) and the standard deviation (s
¼ 1.61) was used to classify molecules into risk categories. A
score of < 8.35 + 1s was considered high-risk, whereas the
other risk categories were as follows: 8.35 + 1s < medium high
< 8.35 + 2s, 8.35 + 2s < medium low risk < 8.35 + 3s, and
Low risk > 8.35 + 3s (Fig. 1A and ESI Fig. 9†). Docking scores
were then plotted against the % inhibition of IL-1b release at 10
mM as determined above (Fig. 1B). From this we were able to
determine a sub-set of molecules with high (>80%) inhibition of
IL-1b release at 10 mM and low predicted COX activity (Fig. 1C).
For this sub-set COX inhibitory activity was measured using
recombinant COX1 and COX2 enzymes and conrmed that at
10 mM, where we observed signicant inhibition of IL-1b release
in a cellular assay, these NVR molecules were devoid of COX
inhibitory activity (ESI Fig. 10†).
We screened this sub-set of molecules with high IL-1b inhi-
bition and no COX activity at a range of concentrations in order
to determine their IC50 values against LPS and ATP-induced IL-
1b release in primary BMDMs (Fig. 2A and ESI Fig. 11†). NLRP3
activation is associated with a number of diseases, including
those of the central nervous system (CNS), making it an
attractive therapeutic target.1,8 To obtain information about the
likelihood of CNS permeability of these molecules, multipa-
rameter optimisation (MPO,9) and blood–brain barrier (BBB,10)
scores were also generated based on physicochemical proper-
ties (Fig. 2A and ESI Fig. 9†), where scores $ 4 indicate greater
likelihood of CNS activity.9,10 Further structure activity rela-
tionship (SAR) analysis of this subset showed the importance ofwhite arrows and (C) quantified and presented as a percentage versus v
Western blot of BMDM cell lysates and supernatants assessing IL-1b, cas
with LPS (1 mg ml1; 4 h) prior to treatment with either NVR-12 (10 mM), M
with ATP (5 mM, 1 h) (n ¼ 3). (E–G) Primary murine BMDMs were pre-trea
the addition of LPS (1 mg ml1; 4 h) (n ¼ 3); (E) TNF and (F) IL-6 release w
was assessed by western blot in cell lysates (n¼ 4). (H) LPS-primed (1 mgm
(10 mM) or vehicle (DMSO; 0.5%) for 15 min prior to the addition of imiqu
(right). For hypotonicity experiments, isotonic buffer (340 mOsm kg1) w
with either NVR-12 (10 mM), MCC950 (10 mM) or vehicle (DMSO; 0.5%) an
were pre-treated with NVR-12 (10 mM), MCC950 (10 mM), Ac-YVAD-CMK
poly(dA:dT) (1 mgml1) or treatedwith lipofectamine alone for 4 h (n¼ 8).
1b release was assessed by ELISA, where data are shown as mean  S.E.M
formation determined by a one-tailed, one-sample t-test with Holm–Sid
by one-way ANOVA with Dunnett's (E, F and I) or Holm–Sidak (J) post ho
two-way ANOVAwith Dunnett's correction. Data were assessed for norm
test, respectively, and transformed where appropriate.
11726 | Chem. Sci., 2020, 11, 11720–11728an acid group, with substituents well tolerated on the le hand
side (LHS), and the requirement for a lipophilic aryl ring on the
right hand side (RHS) (Fig. 2B).
The mechanism of action of the selected sub-set of NVRs was
then further characterised. NVR-12 (which inhibited LPS and
ATP induced IL-1b release with an IC50 of 1 mM (Fig. 2A and C))
is presented as a representative compound in this character-
isation, with the other selected best compounds included in
ESI.† To test if NVR12 inhibited Cl channels we tested its
effects against hypotonicity-induced Cl ux using I quench-
ing of halide-sensitive YFP H148Q/I152L11 in HeLa cells
(Fig. 3A). In this model, I enters the cell through open Cl
channels to induce quenching of YFP. In response to hypotonic
shock YFP uorescence was immediately quenched, which was
inhibited by NVR-12 (Fig. 3A). NVR-12 prevented the formation
of ASC specks in LPS-primed-ASC-mCherry iBMDMs stimulated
with ATP (Fig. 3B, C and ESI Fig. 12†). The inhibitory effects of
NVR-12 on ATP-induced processing of pro-IL-1b, caspase-1, and
gasdermin D were also shown by western blot (Fig. 3D).
Signicant levels of TNF and IL-6 were produced in response to
LPS alone and in the presence of NVR-12 or MCC950 (Fig. 3E
and F), and NVR-12 did not inhibit LPS-induced NLRP3 and pro-
IL-1b expression (Fig. 3G), suggesting that the NVRs act down-
stream of priming.
Interestingly NVR-12 did not inhibit NLRP3 activation in
response to the K+ efflux-independent NLRP3 agonist imiqui-
mod, but did inhibit hypotonicity-induced NLRP3 activation
(Fig. 3H and ESI Fig. 13†). So far we have focussed on the
inhibition of the canonical NLRP3 activation pathway. The
‘alternative’ NLRP3 pathway has been described in primary
human monocytes where LPS treatment alone activates NLRP3-
dependent IL-1b release.12 LPS-induced IL-1b release occurs
independently of K+ ion efflux.12 We tested the effects of our
NVR sub-set against NLRP3-dependent IL-1b release from
primary human monocytes in response to LPS. LPS-induced IL-
1b release was inhibited by the direct NLRP3 inhibitor MCC950
but not by NVRs (Fig. 3I and ESI Fig. 14†). AIM2 and NLRC4
inammasomes can be activated by transfection of poly(dA:dT)
and agellin respectively.13 The effects of the NVRs were specic
to NLRP3 as NVRs had no effect on AIM2 or NLRC4 inam-
masome dependent IL-1b release (Fig. 3J and ESI Fig. 15†)ehicle (n ¼ 4). Control (Con) is no ATP stimulation (DMSO; 0.5%). (D)
pase-1 and GSDMD processing. Primary murine BMDMs were treated
CC950 (10 mM) or vehicle (DMSO; 0.5%) for 15 min before stimulation
ted with either NVR-12 (10 mM), or MCC950 (10 mM) for 15 min prior to
as measured by ELISA (n ¼ 3), and (G) NLRP3 and pro-IL-1b expression
l1; 4 h) BMDMswere pre-treated with either NVR-12 (10 mM), MCC950
imod (IQ, 75 mM; 2 h) (left), or hypotonic solution (117 mOsm kg1; 4 h)
as used as a control (n ¼ 4). (I) Human CD14+ monocytes were treated
d LPS (1 mg ml1; 20 h) (n ¼ 6). (J) LPS-primed BMDMs (1 mg ml1; 4 h)
(100 mM) for 15 min followed by transfection with flagellin (1 mg ml1),
(E, F, H–J) Supernatants were collected and (E) TNF, (F) IL-6 or (H–J) IL-
. (C) **p < 0.01, ****p < 0.0001 significant difference from 100% speck
ak correction. (E, F, I and J) **p < 0.01, and ****p < 0.0001 determined
c analysis. (H) *p < 0.05, **p < 0.01 and ****p < 0.0001 determined by
ality and homoscedasticity by performing a Shapiro–Wilks and Levene's
This journal is © The Royal Society of Chemistry 2020
Edge Article Chemical Sciencesuggesting the NVRs specically inhibit NLRP3. These data
suggesting a K+ dependence are consistent with our recent
report using ion substitution experiments to isolate the Cl
dependence of ASC polymerisation, a feature of the canonical
K+ efflux-dependent NLRP3 activation pathway.14 This discovery
offers an advantage over directly targeting the NLRP3 protein
where we can now target the canonical K+-dependent pathway
in diseases where ASC speck formation is considered to drive
disease pathology such as Alzheimer's disease,15,16 without tar-
geting systemic peripheral NLRP3 responses to infection, thus
reducing the potential of immune-suppression.
Understanding and targeting the NLRP3 inammasome in
disease has become an intensely researched subject.17 Initially
studied as it inhibited the anion exchange activity of the ABC
transporter ABC1, the sulfonylurea glyburide was found to
inhibit ATP-induced IL-1b release from macrophages.18 Further
work showing that diarylsulfonylureas were potent inhibitors of
IL-1b release,19 eventually led to their direct target being iden-
tied to be NLRP3.4,20 Our work here showing that the NVRs do
not inhibit K+ efflux-independent NLRP3 activation conrm
that they are not direct NLRP3 inhibitors. Other NLRP3 inhib-
itingmolecules have been described, many of which target parts
of the activation pathway rather than NLRP3 directly (e.g.21). We
discovered that fenamate NSAIDs have the potential to be
repurposed as NLRP3 inhibitors by virtue of their ability to
inhibit Cl channels.6 Starting with a fenamate scaffold, we
isolated and enhanced the Cl channel and NLRP3 inhibiting
potential to develop new urea analogues that have no effect on
COX enzymes, thus negating a potentially harmful side effect of
these molecules.
There are several pathways leading to the activation of
NLRP3 which have been termed the canonical, non-canonical,
and alternative pathways.17 The fact that the NVRs do not
inhibit the alternative pathway in LPS treated primary human
monocytes strongly suggests that they are not direct inhibitors,
but rather work by inhibiting Cl channels that link to the K+
efflux dependent canonical pathway of NLRP3 activation. This
aspect now allows the possibility of inhibiting only Cl sensitive
pathways when they are known to contribute to disease and
avoid inhibiting NLRP3 responses to infection such as the
alternative pathway in monocytes. Our previous research
showed that Cl efflux is essential for NLRP3-dependent ASC
oligomerisation and formation of the ASC speck.14 Thus NVR
based molecules could be used to inhibit NLRP3-dependent
inammation where the K+ efflux-dependent ASC speck is
known to be important. NLRP3-dependent ASC specks are
thought to underpin the damaging inammation that occurs in
Alzheimer's disease16 and Parkinson's disease.22 Although the
MPO and BBB scores described above suggest that the NVRs
would not easily penetrate the brain, they can form the basis for
subsequent molecules.
Conclusions
In summary, we present a model for how a repurposed drug can
be further developed to enhance desirable properties and
remove unwanted effects. In doing so we discovered thatThis journal is © The Royal Society of Chemistry 2020inhibition of Cl sensitive pathways provides a way of inhibiting
K+ efflux-dependent pathways specically, which may offer
therapeutic advantages in certain contexts. The specic target of
the NVRs remains unknown although chloride intracellular
channel proteins (CLICs 1–6)23,24 are known to contribute to
NLRP3 inammasome activation.25,26 Future studies will deter-
mine whether the CLICs or alternative Cl channels or trans-
porters are the molecular targets of the NVRs, and will also
address the mechanisms through which Cl regulates NLRP3.Conflicts of interest
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